F0806
Factor IX human
aqueous glycerol solution, ≥145 units/mg protein
Sinónimos:
Christmas factor, Plasma thromboplastin component
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
biological source
human
Quality Level
form
aqueous glycerol solution
specific activity
≥145 units/mg protein
mol wt
55 kDa
technique(s)
ligand binding assay: suitable
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... F9(2158)
¿Está buscando productos similares? Visita Guía de comparación de productos
General description
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
Application
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Linkage
View this factors role in the Coagulation Cascade
Unit Definition
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
Physical form
Aqueous solution containing 50% (v/v) glycerol
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease.
Alkim H., et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2011)
Double trouble: Duchenne muscular dystrophy and hemophilia.
Muge Gokce et al.
Pediatric blood & cancer, 60(3), 525-525 (2012-12-21)
Sweta Gupta et al.
British journal of haematology, 161(3), 424-433 (2013-02-26)
This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients with moderate or severe haemophilia. Two-hundred and eighty-six males, 17%
History of prophylaxis.
E Berntorp
Haemophilia : the official journal of the World Federation of Hemophilia, 19(2), 163-165 (2013-02-20)
Keiichiro Kume et al.
Internal medicine (Tokyo, Japan), 46(17), 1323-1329 (2007-09-11)
Recent investigations suggest that activation of coagulation and fibrinolysis occurs in patients with ulcerative colitis (UC). However, the role of the hypercoagulable state in UC has not been determined. On the other hand, there are no reports dealing with coagulation
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico